To the Editor,
In the Patient Monitoring section of the Guidelines to the Practice of Anesthesia -Revised Edition 2016, 1 the use of a peripheral nerve stimulator is not required when neuromuscular blocking drugs are used. As the Guidelines have stipulated for years, a nerve stimulator only needs to be ''exclusively available for each patient.' ' We know that even in the current era of shorter-acting neuromuscular blockers, such as rocuronium and atracurium, residual neuromuscular blockade is common in patients in Post Anesthesia Care Units. Furthermore, this residual blockade is associated with significant impairment in pulmonary function and upper airway dysfunction. This patient safety issue was summarized recently by the president of the Anesthesia Patient Safety Foundation. 2 We know too that qualitative evaluation of the patient's neuromuscular condition using tactile assessment of the response to train-of-four, double-burst, or tetanic stimulation is inferior to quantitative neuromuscular monitoring using acceleromyography. 3 Unfortunately, devices for quantitative assessment of the neuromuscular status are currently not widely available.
As a minimum, the Guidelines should be revised to state that qualitative assessment of neuromuscular function with a nerve stimulator is required when neuromuscular blocking drugs are used. Complying with this more rigorous guideline would not entail any significant costs because nerve stimulators are currently required to be available at every anesthesia work station. 1 In addition to this change, including a statement that quantitative assessment is strongly recommended could be the impetus for development and deployment of devices that provide accurate quantitative assessment of neuromuscular function, with the ultimate goal of eliminating residual postoperative neuromuscular blockade.
Conflicts of interest None declared.
Editorial responsibility This submission was handled by Dr. Hilary P. Grocott, Editor-in-Chief, Canadian Journal of Anesthesia.
